期刊文献+

补肾活血方对帕金森病大鼠多巴胺能神经元的保护作用及机制 被引量:11

Protective Effects and Mechanism of Bushen Houxue Fang on Parkinson's Disease Rat Dopaminergic Neurons
原文传递
导出
摘要 目的:观察补肾活血方对6-羟基多巴胺(6-OHDA)所致帕金森病大鼠黑质多巴胺(DA)能神经元的保护作用。方法:每只雄性SD大鼠黑质内1次性注射6-OHDA 4μL(含9.0μg 6-OHDA和8.8μg抗坏血酸)制作帕金森病(PD)大鼠模型。分别以不同药物灌胃15 d的方式进行治疗。分为正常对照组(生理盐水90 mg·kg-1),模型组(生理盐水90 mg·kg-1)、西药美多巴治疗组(美多巴20 mg·kg-1)、补肾活血方高、中、低(15,10,5 g·kg-1)6组,通过行为学检测、免疫组化法测定黑质酪氨酸羟化酶(TH)、黑质中超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px),观察补肾活血方对DA能神经元的保护作用。结果:1模型组引起典型的右侧旋转,补肾活血方高剂量组和美多巴组与模型组相比旋转圈数减少有显著性差异(P<0.05)。2美多巴组及补肾活血方高剂量组与模型组比较,黑质SOD活性增高(P<0.05),GSH-Px活性也增高(P<0.01),而MDA含量降低(P<0.01)。3TH免疫组化结果表明,与正常组比较PD模型组神经元数量明显减少(P<0.01),甚至消失,神经元胞体萎缩,突起不清晰。补肾活血方高剂量组及美多巴组大鼠黑质TH阳性神经元数量较多,胞体较大,突起明显。结论:补肾活血方对6-OHDA所致帕金森病大鼠黑质DA能神经元损伤具有保护作用,其作用机制可能是通过抗氧化应激及提高黑质酪氨酸羟化酶水平实现的。 Objective:Observe the protective effects of Bushen Houxue fang (BSHXF) on 6-hydroxydopamine (6-OHDA) type of Parkinson's disease in substantia nigra of injection of 6-OHD rat dopaminergic neurons.Method:Substantia nigra once injection of 4 μL 6-OHDA to model the Parkinson's disease rat,and divide those models into 6 different groups:normal control (0.9% NaCl) model (0.9% NaCl),madopar comparison (20 mg·kg-1 madopar),high (15 g·kg-1 BSHXF),mid (10 g·kg-1) and low (5 g·kg-1) dosage of BSHXF.Each group intragastric administration one time every day for 15 days.Using ethology detection,immunohistochemistry to determine substantia nigra tyrosine hydroxylase,SOD,MDA and GSH-Px,then observe the protective effects of Bushen Houxue fang on DA neurons.Result:①Group model rotates clockwise (11.27 ± 1.68) lap/min,there is significant difference (P < 0.05) among High dosage of BSHXF group (6.35 ± 1.49 lap/min,madobar group (5.76 ± 1.23) lap/min and model group.②Madobar and high dosage group compare to model group have increasing activity of substantia nigra (P < 0.05),as well as GSH-Px (P <0.01).Meanwhile,high dosage of BSHXF and madobar have similar increase in SOD,GSH-Px and decrease in MDA.③TH immunohistochemistry result shows BSHXF high dosage and madobar group rat substantia nigra TH have large number of positive neuron,large soma size,significant outgrowth,the comparison of the two groups shows no statistical difference.PD model group has significant decrease in the number of neuron (P < 0.01),even disappearing,neuron soma atrophy,little outgrowth.Conclusion:There are protective effects of BSHXF on 6-OHDA type of Parkinson's disease in substantia nigra of rat dopaminergic neurons,its effect mechanism could achieved through anti-oxidative stress and increase level of tyrosine hydroxylase in substantia nigra.
出处 《中国实验方剂学杂志》 CAS 北大核心 2014年第21期175-179,共5页 Chinese Journal of Experimental Traditional Medical Formulae
基金 2011年陕西省中医管理局项目(2011JC-36)
关键词 补肾活血方 多巴胺能神经元 酪氨酸羟化酶 超氧化物歧化酶 丙二醛 谷胱甘肽过氧化物酶 Bushen Houxue fang dopaminergic neuron tyrosine hydroxylase superoxide dismutase malondialdehyde glutathione peroxidase
  • 相关文献

参考文献15

  • 1Kwon D H, Kim J M, Oh S H, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease[J]. Ann Neurol, 2012,71(2):267. 被引量:1
  • 2陈生弟,王刚.帕金森病药物治疗中的若干问题[J].中华神经科杂志,2008,41(3):145-146. 被引量:2
  • 3包新民,舒斯云著..大鼠脑立体定位图谱[M].北京:人民卫生出版社,1991:181.
  • 4Zhang Zhen-Xin, Gustavo C Roman, Zhen Hong, et al. Parkinson's disease in China: prevalence in Beijing, Xian and Shanghai[ J] Lancet ,2005 ( 365 ) :595. 被引量:1
  • 5陈生弟编著..帕金森病临床诊治手册[M].北京:人民卫生出版社,2008:188.
  • 6Przedborski S, Isch iropou los H. Reactive oxygen and n itrogen species: weapons of neuronal destruction in models of Parkinson's disease [ J ]. Antioxid Redox Signal, 2005, 7 (5/6) : 685. 被引量:1
  • 7Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link[ J]. Exp Neurol, 2005, 193(2): 279. 被引量:1
  • 8Buchmann C,Arlt S,Kontush A, et al. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influence by antiparkinsonian medicine[J]. Neurobiol Dis ,2004 ( 15 ) : 160. 被引量:1
  • 9Maragakis N J, Jack son M, Ganel R, et al. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice[J]. NeurosciLett, 2003, 338(2): 107. 被引量:1
  • 10Sanchez-Iglesias S, Rey P, Mendez-Alvarez E, et al. Time course of brain oxidative damage caused by intrastriatal administration of 6- hydroxydopamine in a rat model of Park inson's disease [ J]. Neurochem Res, 2007, 32(1): 99. 被引量:1

二级参考文献42

  • 1董青,李焰生.帕金森病非运动症状的研究进展[J].临床神经病学杂志,2008,21(4):310-312. 被引量:32
  • 2陈海波.帕金森病的左旋多巴治疗史及现状[J].中华老年医学杂志,2004,23(7):451-452. 被引量:15
  • 3陈生弟.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. 被引量:102
  • 4The National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006 : 60-110. 被引量:1
  • 5Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskincsia (an evidence-based review ): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2006, 66: 983-995. 被引量:1
  • 6Horstink M, Tolosa E, BonucceUi U, et al. Review of the therapeutic management of Parkinson' s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part Ⅱ: late (complicated) Parkinson' s disease. EurJ Neurol, 2006, 13: 1186-1202. 被引量:1
  • 7Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson ' s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part Ⅰ : early (uncomplicated) Parkinson' s disease. Eur J Neurol, 2006, 13 : 1170-1185. 被引量:1
  • 8Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology, 2007, 68: 45-50. 被引量:1
  • 9Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson' s disease. Expert Opin Investig Drugs, 2005, 14: 729-738. 被引量:1
  • 10Muller T. Dopaminergic substitution in Parkinson' s disease. Expert Opin Pharmacother, 2002, 3 : 1393-1403. 被引量:1

共引文献27

同被引文献180

引证文献11

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部